SPRED1 and chronic myelogenous leukemia, BCR-ABL1 positive: Therefore, bone marrow endothelial cell-secreted miR-126 could enhance the transition of tyrosine kinase inhibitor-treated chronic myeloid leukemia cells to G0 phase via targeting sprouty-related EVH1 domain-containing protein 1, thus promoting alterations in the RAS/MAPK/extracellular signal-regulated kinase pathway [39].